Atenolol is a ß1 receptor specific antagonist, a drug belonging to the group of ß-blockers, a class of drugs used primarily in cardiovascular diseases. Introduced in 1976, atenolol was developed as a replacement for propranolol in the treatment of hypertension. Atenolol (trade name Tenormin) can be used to treat cardiovascular diseases and conditions such as hypertension, coronary heart disease, arrhythmias, angina (chest pain) and to treat and reduce the risk of heart complications following myocardial infarction (heart attack)
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is hurting our loved ones — even those that walk on four legs. Researchers from the University of Pennsylvania documented the recovery of an 11-year old indoor housecat living in Delaware who first presented to the veterinary hospital after experiencing distressing gastrointestinal symptoms.
Heart attacks, strokes and other cardiovascular incidents can be cut by 20 to 40 per cent through use of a polypill which combines three blood pressure medications and a lipid lowering medication taken alone or with aspirin.
A single, daily pill combining blood pressure and cholesterol medications, along with the addition of a daily dose of aspirin, reduced cardiovascular disease events in people at risk for heart disease, according to late-breaking research presented today in a late-breaking clinical trial presentation at the American Heart Association's Scientific Sessions 2020.
A drug costing less than 2 euros per dose could reduce the long term consequences of a heart attack, benefitting millions of patients. Metoprolol, a member of the beta-blocker class of drugs that has been in use for more than 40 years, has been found to have unique cardioprotective properties.
None of the 41 most common high blood pressure medications increased the risk of depression, while nine medications appeared to lower it, according to a study from Denmark, published today in Hypertension, an American Heart Association journal.
Blood pressure and cholesterol lowering drugs continue to improve survival in patients with hypertension after more than a decade, according to late breaking results from the ASCOT Legacy study presented at ESC Congress 2018 and published in The Lancet.
A new treatment for Marfan syndrome, a rare genetic disease that can lead to heart problems, works as well as the currently recommended medical therapy, beta blockers, according to an article in the New England Journal of Medicine.
An investigational treatment for Marfan syndrome is as effective as the standard therapy at slowing enlargement of the aorta, the large artery of the heart that delivers blood to the body, new research shows. The findings indicate a second treatment option for Marfan patients, who are at high risk of sudden death from tears in the aorta.
The publication of the new joint ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management introduces a number of recommendations in the field. Among other topics, the Guidelines include updated information on the use of clinical indices and biomarkers in risk assessment, and the use of novel anticoagulants, statins, aspirin and beta-blockers in risk mitigation.
Beta blockers may boost survival in patients undergoing definitive radiotherapy for non-small-cell lung cancer, suggests research published in the Annals of Oncology.
Merz, Inc. today announced the acquisition of CUVPOSA (glycopyrrolate) oral solution for pediatric chronic severe drooling associated with neurologic conditions such as cerebral palsy.
Users of common antihypertensive drugs, such as hydrochlorothiazide and nifedipine, may be at increased risk for developing lip cancer.
A new study has found that, contrary to current thinking, taking beta blockers that treat high blood pressure does not decrease a person's risk of developing colorectal cancer. Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the study also revealed that even long-term use or subtypes of beta blockers showed no reduction of colorectal cancer risk.
Weight gain or loss may not always be caused by what you eat or how much you exercise. For some, it's the medicines you're taking.
The American Academy of Neurology is releasing an updated guideline on how to best treat essential tremor, which is the most common type of tremor disorder and is often confused with other movement disorders such as Parkinson's disease.
The AF AWARE campaign today, at the European Society of Cardiology (ESC) Congress 2011 in Paris, announces the launch of the Atrial Fibrillation in Primary Care (AFIP) tool, developed to help primary care physicians (PCPs) with early diagnosis and optimal management of patients with atrial fibrillation.
A study published in the July issue of The American Journal of Medicine, reports that among hypertensive patients with coronary artery disease, chronic self-reported use of non-steroidal anti-inflammatory drugs (NSAIDs) was associated with an increased risk of adverse events during long-term follow-up. Long-term NSAID use is common for treatment of chronic pain.
A side effect of many commonly used drugs appears to increase the risks of both cognitive impairment and death in older people, according to new research led by the University of East Anglia.
British scientists warn that well known brands of hay fever tablets, painkillers and sleeping pills pose a previously unknown threat to elderly people’s health when taken together. Many are available over the counter at pharmacies as well as being prescribed by GPs, nurses and chemists they said.
Shionogi Inc., the U.S.-based group company of Shionogi & Co., Ltd., today announced the U.S. commercial availability of CUVPOSA™ (glycopyrrolate) oral solution, the first and only FDA-approved treatment to reduce chronic severe drooling in patients aged 3 to 16 with neurologic conditions associated with problem drooling, such as cerebral palsy.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.